Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by POXEL SA
< Previous
1
2
Next >
Poxel to Report Its 2023 Annual Results by the End of April 2024
March 28, 2024
From
POXEL SA
Via
Business Wire
Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update
September 26, 2023
From
POXEL SA
Via
Business Wire
Poxel to Report 2023 First Half-Year Results and host a video conference on September 26, 2023
September 07, 2023
From
POXEL SA
Via
Business Wire
Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference
July 18, 2023
From
Poxel SA
Via
Business Wire
Poxel, winner of the 2023 edition of the I-nov contest
July 05, 2023
From
POXEL SA
Via
Business Wire
Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris
June 30, 2023
From
Poxel SA
Via
Business Wire
Poxel Announces Results from June 21, 2023 Ordinary Annual and Extraordinary General Meeting
June 23, 2023
From
POXEL SA
Via
Business Wire
Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023
May 16, 2023
From
Poxel SA
Via
Business Wire
Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference
May 11, 2023
From
Poxel SA
Via
Business Wire
Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility
March 23, 2023
From
POXEL SA
Via
Business Wire
Poxel to Report its 2022 Full Year Results by the End of March 2023
March 22, 2023
From
Poxel SA
Via
Business Wire
Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event
March 15, 2023
From
Poxel SA
Via
Business Wire
Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology
March 07, 2023
From
POXEL SA
Via
Business Wire
Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 01, 2023
From
POXEL SA
Via
Business Wire
Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy
January 25, 2023
From
POXEL SA
Via
Business Wire
Poxel Announces Upcoming Participation at Investor Conferences
January 04, 2023
From
Poxel SA
Via
Business Wire
Poxel Announces its Financial Calendar for 2023
January 03, 2023
From
Poxel SA
Via
Business Wire
Poxel Announces Drawdown of the Remaining Two Tranches of its Equity-linked Financing Facility and Provides Corporate Update
December 22, 2022
From
Poxel SA
Via
Business Wire
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022
November 08, 2022
From
Poxel SA
Via
Business Wire
Poxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
November 07, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces Upcoming Participation at the Jefferies London Healthcare Conference
November 07, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference
October 13, 2022
From
Poxel SA
Via
Business Wire
Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
October 12, 2022
From
Poxel SA
Via
Business Wire
Availability of Poxel's 2022 Half-Year Financial Report
October 04, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
October 03, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone
September 21, 2022
From
Poxel SA
Via
Business Wire
Poxel Reports Financial Results for First Half 2022 and Provides a Corporate Update
September 21, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone
August 30, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility
August 08, 2022
From
Poxel SA
Via
Business Wire
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022
August 08, 2022
From
Poxel SA
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.